BOSTON, Aug. 26, 2002 (PRIMEZONE) -- Biotechnology stocks have begun to rebound as the industry moves ahead with new products and expanded possibilities. Get the latest updates from biotech executives at the Boston Biotech Stocks Forum September 14 at the Seaport Hotel/World Trade Center - Boston.
Investors can attend this Forum either in person at the Seaport Hotel/World Trade Center - Boston or online via www.informedinvestors.com from 9:00 a.m.-11:00 a.m. EST. The Forum will give Investors the opportunity to hear directly from company executives and get their investment information straight from the source.
The Informed Investors Forum will have senior executives from Avitar (AMEX:AVR), Bradley Pharmaceuticals (Nasdaq:BPRX), and other firms speaking for approximately 30 minutes each with PowerPoint presentations. A keynote presentation by Lynn Sutherland will add perspective to the Forum. Investors are invited to submit questions directly or by email to the executives. The forum will also be archived on www.informedinvestors.com, www.vcall.com and www.investorconference.com.
Avitar, Inc., headquartered in Canton, Massachusetts, is a diagnostics company that develops, manufactures and markets innovative and proprietary medical devices in two major areas: the oral fluid diagnostics market and the disease & clinical testing market. Oral fluid diagnostics includes the drugs-of-abuse testing market estimated to be worth $1.5 billion encompassing the corporate workplace and criminal justice markets. Avitar's products include ORALscreen(tm), the world's first non-invasive, rapid, onsite oral fluid test for drugs-of-abuse, and HAIRscreen(tm), a laboratory-based hair test for detecting long-term drug abuse. In the $20 billion disease & clinical testing market, Avitar is currently developing products that will address the conditions of Lyme disease, influenza and diabetes, as well as pregnancy. For more information, see Avitar's website at www.avitarinc.com.
Bradley Pharmaceuticals, Inc. markets over-the-counter and prescription pharmaceuticals, as well as health-related products. The Company's product line includes dermatological brands (marketed by its wholly owned subsidiary, Doak Dermatologics, Inc.) and nutritional, respiratory and internal medicine brands (marketed by its Kenwood Therapeutics division). All its product lines are manufactured and supplied by independent contractors and marketed primarily to wholesalers. The wholesalers, in turn, distribute its products to retail outlets and healthcare institutions throughout the United States. The Company also sells to distributors in selected international markets.
Informed Investors is the leading producer of online and offline industry-specific investment conferences for individual investors and a member of the WILink suite of PrecisionIR(tm) services serving publicly traded companies and self-reliant investors.
About WILink
Since 1992, WILink plc (www.wilink.com) has helped public companies and mutual funds attract and retain investors. WILink's PrecisionIR(tm) and PrecisionFM(tm) custom investor-marketing programs enable publicly traded companies and mutual funds to deliver tailored and compelling communications to a precisely targeted audience of investors. This year, WILink will make more than 7 million investor introductions for over 4,200 corporate clients through PrecisionIR(tm) and PrecisionFM(tm) programs, which include the Annual Reports Service, the Fund Info Service, Informed Investors Forums (www.informedinvestors.com) and Vcall(r) webcasting (www.vcall.com). WILink's InstitutionalReach(tm) database and partnerships with over 230 leading financial channels in 14 countries, including The Wall Street Journal, Financial Times, Barron's and Yahoo! Finance, ensure clients targeted visibility within the investment community. WILink, Inc., a wholly owned subsidiary of WILink plc (WLK:LSE), began operations in Richmond, Va. in 1993.